VarmX is a technology company.
VarmX has raised $83.0M across 4 funding rounds.
VarmX has raised $83.0M in total across 4 funding rounds.
VarmX has raised $83.0M in total across 4 funding rounds.
VarmX's investors include 2xN, Amadeus Capital Partners, Endeavor Venture Funds, EQT Life Sciences, Qima Ventures, RTW Investments, Atlas Venture, INKEF Capital, BGV (BioGeneration Ventures).
VarmX is a clinical-stage biotech company developing VMX-C001, a recombinant protein designed as a fast, safe, and effective reversal agent for severe bleeding in patients on Factor Xa direct oral anticoagulants (FXa DOACs), enabling urgent surgery with reduced bleeding risk.[1][2][3][4] It serves patients on FXa DOACs—such as those with atrial fibrillation or thrombosis—who face life-threatening bleeds or surgical needs, addressing the critical gap in specific antidotes for this class of blood thinners.[1][3][4] The company has shown strong growth momentum, including a September 2025 strategic collaboration with CSL for full funding of its global Phase 3 EquilibriX-S trial, late-stage development, manufacturing, and pre-launch activities, plus an exclusive option for CSL to acquire the company, with shareholders receiving an initial $117 million upfront and potential milestones.[2][3]
VarmX was founded in 2016 as a spin-off from Leiden University Medical Center (LUMC) by Professor Pieter Reitsma, former head of the Thrombosis and Hemostasis department and a world-leading expert in hemostasis and thrombosis genetics, who co-discovered Factor V Leiden.[1][3] The idea emerged from Reitsma's expertise to create VMX-C001, a modified recombinant blood factor X, targeting unmet needs in FXa DOAC reversal.[3] Early traction included backing from a syndicate of investors like Sound Bioventures, EQT Life Sciences, Ysios Capital, and others, followed by pivotal milestones such as Japanese PMDA waiving Phase 1 trials for VMX-C001 to enable direct Phase 3 entry, leadership strengthening in November 2024, and the transformative CSL partnership in 2025.[1][2][3]
VarmX rides the surging demand for precision anticoagulants amid rising FXa DOAC prescriptions for conditions like atrial fibrillation, where bleeding complications affect millions annually, yet specific reversal agents remain limited.[1][3][4] Timing is ideal post-2025 CSL deal, aligning with global aging populations and post-pandemic surgical backlogs amplifying urgent reversal needs.[2][3] Market forces favor it through regulatory efficiencies (e.g., PMDA waiver) and investor confidence in coagulation therapies, influencing the ecosystem by advancing bypass agents for DOACs and inherited disorders, potentially setting standards for emergency hemostasis.[2][3]
VarmX is poised for Phase 3 success with CSL's full backing, potentially yielding VMX-C001 approval as the go-to FXa DOAC reversal agent by late 2020s, followed by commercialization if the acquisition option exercises.[3] Trends like expanding DOAC use and precision medicine will propel growth, evolving VarmX's influence from innovator to potential CSL-integrated leader in coagulation therapies. This builds on its mission to revolutionize severe bleeding treatment, delivering fast, safe solutions where lives hang in the balance.[1][3][4]
VarmX has raised $83.0M across 4 funding rounds. Most recently, it raised $37.0M Series B in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $37.0M Series B | 2xN, Amadeus Capital Partners, Endeavor Venture Funds, EQT Life Sciences, Qima Ventures, RTW Investments | |
| Jul 1, 2020 | $36.0M Series B | Atlas Venture, Endeavor Venture Funds, EQT Life Sciences, INKEF Capital, Qima Ventures, RTW Investments | |
| Jul 1, 2018 | $9.0M Series A | BGV (BioGeneration Ventures) | |
| Jun 1, 2017 | $1.0M Seed | BGV (BioGeneration Ventures) |